郝軍峰 晉亮 王剛
角質(zhì)形成細(xì)胞抗原提呈功能的研究進(jìn)展
郝軍峰 晉亮 王剛
角質(zhì)形成細(xì)胞不僅形成機(jī)體的物理屏障,同時(shí)具有重要的免疫功能。角質(zhì)形成細(xì)胞在一些疾病狀態(tài)下或者直接受到干擾素γ等細(xì)胞因子的刺激后,可以表達(dá)抗原提呈相關(guān)分子,如主要組織相容性復(fù)合體Ⅱ、細(xì)胞間黏附分子1等,同時(shí)主要組織相容性復(fù)合體Ⅰ也會(huì)發(fā)生改變。有研究表明,活化后的角質(zhì)形成細(xì)胞可以加工并提呈內(nèi)源性或外源性抗原,進(jìn)一步活化抗原特異性T淋巴細(xì)胞。角質(zhì)形成細(xì)胞的這一功能對(duì)闡明相關(guān)皮膚病的發(fā)病機(jī)制及作出針對(duì)性的靶向治療具有重要意義。但同經(jīng)典的抗原提呈細(xì)胞相比,角質(zhì)形成細(xì)胞發(fā)揮抗原提呈功能可能還存在著一定的局限性。
角蛋白細(xì)胞;抗原呈遞;T淋巴細(xì)胞;主要組織相容性復(fù)合物;細(xì)胞黏附分子
皮膚是機(jī)體最大的器官,同時(shí)也是最大的免疫器官,既能夠發(fā)揮固有免疫應(yīng)答又可以發(fā)揮適應(yīng)性免疫應(yīng)答[1]。角質(zhì)形成細(xì)胞作為皮膚表皮的主要組成細(xì)胞,是皮膚免疫系統(tǒng)重要的組成部分。研究表明,角質(zhì)形成細(xì)胞可以在免疫應(yīng)答過(guò)程中起抗原提呈作用,其表面可以表達(dá)專職抗原提呈細(xì)胞所特有的分子,而且可以進(jìn)一步活化抗原特異性T淋巴細(xì)胞。這對(duì)于角質(zhì)形成細(xì)胞被活化的相關(guān)皮膚病發(fā)病機(jī)制的研究非常重要。
1.1 角質(zhì)形成細(xì)胞在直接受到某些細(xì)胞因子刺激時(shí)的表達(dá):角質(zhì)形成細(xì)胞在受到細(xì)胞因子,如干擾素(IFN)γ刺激后會(huì)表達(dá)專職抗原提呈細(xì)胞,如巨噬細(xì)胞、樹突細(xì)胞表面所特有的膜分子MHC-Ⅱ、ICAM-1 等[2-3]。Zhou 等[4]觀察到刺激后角質(zhì)形成細(xì)胞膜表面MHC-Ⅰ的表達(dá)較刺激前增加。上述改變?yōu)榻琴|(zhì)形成細(xì)胞發(fā)揮抗原提呈提供了必備條件。Sch?nefuss等[5]研究發(fā)現(xiàn),組織蛋白酶S參與了角質(zhì)形成細(xì)胞的分化及MHC介導(dǎo)的抗原提呈,作者將組織蛋白酶S特異性抑制后,IFN-γ刺激人永生角質(zhì)形成細(xì)胞引起的MHC-Ⅱ的增高在很大程度上被減弱。作為抗原提呈細(xì)胞活化T淋巴細(xì)胞的共刺激分子CD80、CD86,角質(zhì)形成細(xì)胞在受到IFN-γ、葡萄球菌內(nèi)毒素B、脂多糖、糖皮質(zhì)激素、白細(xì)胞介素2、4等刺激下均不會(huì)出現(xiàn) CD80、CD86 的變化[6]。
1.2 角質(zhì)形成細(xì)胞在疾病狀態(tài)下的表達(dá):研究者們?cè)谕怅幧掀?nèi)瘤變、淋巴細(xì)胞血管炎、紅斑狼瘡、硬斑病、白癜風(fēng)、線狀苔蘚、皮膚T細(xì)胞淋巴瘤、過(guò)敏性接觸性皮炎、銀屑病等疾病表皮的角質(zhì)形成細(xì)胞上觀察到 MHC-Ⅱ和(或)ICAM-1 的表達(dá)[7-8]。另有人觀察到中毒性表皮壞死松解癥的角質(zhì)形成細(xì)胞MHC-Ⅰ表達(dá)增高[9]。外陰上皮內(nèi)瘤變及外陰癌的角質(zhì)形成細(xì)胞MHC-Ⅰ表達(dá)降低[10]。說(shuō)明角質(zhì)形成細(xì)胞膜分子的改變所引起的抗原提呈在上述疾病的發(fā)病過(guò)程中發(fā)揮了作用。
作者單位:710032西安,第四軍醫(yī)大學(xué)西京皮膚醫(yī)院
Sharlow等[11]推測(cè),表皮角質(zhì)形成細(xì)胞可能通過(guò)吞噬黑素進(jìn)而傳遞給周圍的黑素小體,認(rèn)為角質(zhì)形成細(xì)胞可能發(fā)揮了吞噬功能。體外實(shí)驗(yàn)方面,Black等[6]研究證實(shí)了活化的角質(zhì)形成細(xì)胞具備這一功能,作者用經(jīng)和未經(jīng)IFN-γ刺激的角質(zhì)形成細(xì)胞與熒光乳膠珠過(guò)夜共孵育,發(fā)現(xiàn)在刺激組細(xì)胞的胞質(zhì)中檢測(cè)到了乳膠珠,未刺激組沒(méi)有檢測(cè)到乳膠珠。緊接著作者分別通過(guò)對(duì)角質(zhì)形成細(xì)胞表面的MHC-Ⅱ分子加載肽段或?qū)⒔琴|(zhì)形成細(xì)胞與抗原蛋白共孵育,體外刺激特異性識(shí)別該MHCⅡ-肽段復(fù)合物的CD4+T淋巴細(xì)胞系,最終導(dǎo)致后者活化,這一過(guò)程可以被氯喹抑制,這一特異性抑制說(shuō)明了角質(zhì)形成細(xì)胞加工外源性的蛋白是通過(guò)內(nèi)體途徑,即外源性抗原加工途徑完成的。
作為有核細(xì)胞,角質(zhì)形成細(xì)胞表面表達(dá)MHC-Ⅰ,若受到細(xì)胞因子如,IFN-γ刺激后表達(dá)增加[4]。Black等[6]將無(wú)IFN-γ刺激的角質(zhì)形成細(xì)胞MHC-Ⅰ加載已知病毒來(lái)源肽段后與特異性識(shí)別該肽段的CD8+T淋巴細(xì)胞共孵育。作者觀察到CD8+T淋巴細(xì)胞的活化,同時(shí)觀察到角質(zhì)形成細(xì)胞被殺傷。角質(zhì)形成細(xì)胞若用IFN-γ預(yù)先刺激后,CD8+T淋巴細(xì)胞被活化及角質(zhì)形成細(xì)胞被殺傷更加明顯。Symington和 Santos[12]觀察到這一殺傷試驗(yàn)中,未用 IFN-γ 刺激的角質(zhì)形成細(xì)胞所造成的活化、殺傷可以被MHC-Ⅰ或T細(xì)胞受體單抗阻斷,但是使用IFN-γ刺激后所造成的殺傷單用上述兩種抗體中的一種活化、殺傷無(wú)法完全被阻斷,尚需要使用淋巴細(xì)胞功能相關(guān)抗原(LFA)1的單抗來(lái)特異性抑制ICAM-1/LFA-1這一共刺激途徑。這說(shuō)明未活化角質(zhì)形成細(xì)胞殺傷Ag/CD3-TCR的環(huán)節(jié)是必需的,活化角質(zhì)形成細(xì)胞的ICAM-1/LFA-1和抗原/CD3-TCR信號(hào)對(duì)于殺傷是必不可少的。這一現(xiàn)象可以解釋為IFN-γ的刺激增強(qiáng)了角質(zhì)形成細(xì)胞抗原提呈的能力,促進(jìn)了ICAM-1表達(dá)增加,共孵育后增強(qiáng)了CD8+T淋巴細(xì)胞活化及角質(zhì)形成細(xì)胞的被殺傷。
Kim 等[13]利用 K14-OVA-Langerin-DTR 轉(zhuǎn)基因小鼠具有特異性抑制表皮中朗格漢斯細(xì)胞的特點(diǎn),通過(guò)骨髓移植特異性排除真皮中的樹突細(xì)胞的干擾,將特異性識(shí)別K14-OVA的T淋巴細(xì)胞注射入轉(zhuǎn)基因小鼠(表皮朗格漢斯細(xì)胞及真皮中的樹突細(xì)胞功能缺陷)皮下3 d后,小鼠表現(xiàn)出了移植物抗宿主病樣的改變,作者認(rèn)為,在這一免疫應(yīng)答過(guò)程中,充當(dāng)抗原提呈細(xì)胞角色的是表皮中活化的角質(zhì)形成細(xì)胞,同時(shí)作者通過(guò)免疫熒光觀察到了角質(zhì)形成細(xì)胞間的MHC-Ⅱ和ICAM-1的表達(dá)。
角質(zhì)形成細(xì)胞在受到細(xì)胞因子如,IFN-γ、腫瘤壞死因子(TNF)α的刺激后活化,證明在炎癥性皮膚病中,能夠分泌上述細(xì)胞因子的T淋巴細(xì)胞存在的重要性。角質(zhì)形成細(xì)胞MHC-Ⅱ及ICAM-1的表達(dá)及局部T淋巴細(xì)胞的浸潤(rùn)在許多皮膚病均存在[7-8,14-15]。Lodi等[16]認(rèn)為,口腔扁平苔蘚發(fā)病機(jī)制可能為CD8+T淋巴細(xì)胞分泌的TNF-α、FasL、顆粒酶B與基底層角質(zhì)形成細(xì)胞表面的TNF-α受體1、Fas及穿孔素引起的膜孔道結(jié)合,通過(guò)細(xì)胞毒性的免疫應(yīng)答方式引起基底層角質(zhì)形成細(xì)胞的破壞。Zhang和Zhou[17]提出綠茶可以抑制抗原提呈、T細(xì)胞活化、增殖以及遷移,提出飲用綠茶可能會(huì)降低口腔扁平苔蘚的發(fā)生率。在闡述Stevens-Johnson綜合征及中毒性表皮壞死松解癥的發(fā)病機(jī)制時(shí),Chung和Hung[18]認(rèn)為,這一免疫應(yīng)答過(guò)程中的抗原提呈細(xì)胞為角質(zhì)形成細(xì)胞,系具有抗原性的藥物(如卡馬西平)與表達(dá)在角質(zhì)形成細(xì)胞表面的HLA分子結(jié)合通過(guò)免疫突觸,細(xì)胞毒性T淋巴細(xì)胞移行至表皮與HLA-肽段(藥物來(lái)源)的復(fù)合物識(shí)別,釋放大量免疫介質(zhì),如FasL、穿孔素、顆粒酶B、顆粒酶素(尤以分泌型的顆粒酶素為著),通過(guò)這些免疫介質(zhì)去殺傷角質(zhì)形成細(xì)胞,導(dǎo)致角質(zhì)形成細(xì)胞的大片壞死,重者形成水皰。van Esch等[15]觀察到HPV感染陽(yáng)性的陰道上皮內(nèi)瘤變及外陰癌角質(zhì)形成細(xì)胞的MHC-Ⅰ減少,使HPV來(lái)源的肽段無(wú)法提呈給T細(xì)胞,機(jī)體對(duì)病毒的適應(yīng)性免疫應(yīng)答缺陷,故該疾病無(wú)法進(jìn)行免疫治療,同時(shí)對(duì)于該病角質(zhì)形成細(xì)胞間局部MHC-Ⅱ的表達(dá),作者認(rèn)為,可能系局部細(xì)胞因子刺激的結(jié)果,未進(jìn)一步給出合理的解釋。Zhou等[4]利用HPV-16-E7轉(zhuǎn)染小鼠,認(rèn)為HPV-16-E7通過(guò)干擾IFN-γ介導(dǎo)的JAK1/JAK2/STAT1/IRF-1信號(hào)轉(zhuǎn)導(dǎo)通路,減少M(fèi)HC-Ⅰ的表達(dá)及其加載的肽段,可能成為HPV16體內(nèi)形成免疫逃逸的原因。
充分了解角質(zhì)形成細(xì)胞的抗原提呈功能對(duì)于研究相關(guān)皮膚病的發(fā)病機(jī)制非常重要,可以找出疾病活化后的角質(zhì)形成細(xì)胞MHC分子上所加載的肽段,從而針對(duì)其T淋巴細(xì)胞表位進(jìn)行靶向治療。值得注意的是,淋巴細(xì)胞浸潤(rùn)的炎癥性皮膚病局部皮損的微環(huán)境非常復(fù)雜,體外用模擬角質(zhì)形成細(xì)胞抗原提呈功能所使用的IFN-γ,無(wú)論從使用的劑量以及與其他細(xì)胞因子的相互作用,都不能完全反映皮損局部的狀態(tài)。不同劑量的IFN-γ以及與其他細(xì)胞因子,如TNF-α等的相互作用會(huì)影響到角質(zhì)形成細(xì)胞的加工和提呈抗原的能力。因此,在研究角質(zhì)形成細(xì)胞抗原提呈功能時(shí),應(yīng)密切結(jié)合疾病所處的實(shí)際微環(huán)境。盡管如此,活化后的角質(zhì)形成細(xì)胞不能完全發(fā)揮經(jīng)典的抗原提呈細(xì)胞的所有功能,因抗原提呈細(xì)胞除加工抗原外,還需要遷移至次級(jí)淋巴器官[19]。
[1] Sanford JA,Gallo RL.Functions of the skin microbiota in health and disease[J].Semin Immunol,2013,25(5):370-377.
[2] Madonna S,Scarponi C,Doti N,et al.Therapeutical potential of a peptide mimicking the SOCS1 kinase inhibitory region in skin immune responses[J].Eur J Immunol,2013,43(7):1883-1895.
[3] Scarponi C,Butturini E,Sestito R,et al.Inhibition of inflammatory and proliferative responses of human keratinocytes exposed to the sesquiterpene lactones dehydrocostuslactone and costunolide [J/OL].PLoS One,2014,9(9):e107904[2014-09-16].http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0107904.
[4] Zhou F,Chen J,Zhao KN.Human papillomavirus 16-encoded E7 protein inhibits IFN-γ-mediated MHC class Ⅰ antigen presentation and CTL-induced lysis by blocking IRF-1 expression in mouse keratinocytes [J].J Gen Virol,2013,94(Pt 11):2504-2514.
[5] Sch?nefuss A,Wendt W,Schattling B,et al.Upregulation of cathepsin S in psoriatic keratinocytes [J].Exp Dermatol,2010,19(8):e80-e88.
[6] Black AP,Ardern-Jones MR,Kasprowicz V,et al.Human keratinocyte induction of rapid effector function in antigenspecific memory CD4+and CD8+T cells [J].Eur J Immunol,2007,37(6):1485-1493.
[7] Abrams JR,Kelley SL,Hayes E,et al.Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques,including the activation of keratinocytes,dendritic cells,and endothelial cells [J].J Exp Med,2000,192(5):681-694.
[8] Centanni JM,Straseski JA,Wicks A,et al.StrataGraft skin substitute is well-tolerated and is not acutely immunogenic in patients with traumatic wounds:results from a prospective,randomized,controlled dose escalation trial[J].Ann Surg,2011,253(4):672-683.
[9] Schwartz RA,McDonough PH,Lee BW.Toxic epidermal necrolysis:Part I.Introduction,history,classification,clinical features, systemic manifestations, etiology, and immunopathogenesis [J].J Am Acad Dermatol,2013,69(2):173.
[10] van Esch EM,Tummers B,Baartmans V,et al.Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy[J].Int J Cancer,2014,135(4):830-842.
[11] Sharlow ER,Paine CS,Babiarz L,et al.The protease-activated receptor-2 upregulates keratinocyte phagocytosis [J].J Cell Sci,2000,113(Pt 17):3093-3101.
[12] Symington FW,Santos EB.Lysis of human keratinocytes by allogeneic HLA class I-specific cytotoxic T cells.Keratinocyte ICAM-1 (CD54)and T cell LFA-1 (CD11a/CD18)mediate enhanced lysisofIFN-gamma-treated keratinocytes [J].J Immunol,1991,146(7):2169-2175.
[13] Kim BS,Miyagawa F,Cho YH,et al.Keratinocytes function as accessory cells for presentation of endogenous antigen expressed in the epidermis [J].J Invest Dermatol,2009,129(12):2805-2817.
[14] Aub?ck J,Romani N,Grubauer G,et al.HLA-DR expression on keratinocytes is a common feature of diseased skin [J].Br J Dermatol,1986,114(4):465-472.
[15] van Esch EM,Tummers B,Baartmans V,et al.Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy[J].Int J Cancer,2014,135(4):830-842.
[16] Lodi G,Scully C,Carrozzo M,et al.Current controversies in oral lichen planus:report of an international consensus meeting.Part 1.Viral infections and etiopathogenesis [J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2005,100(1):40-51.
[17] Zhang J,Zhou G.Green tea consumption:an alternative approach to managing oral lichen planus[J].Inflamm Res,2012,61(6):535-539.
[18] Chung WH,Hung SI.Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis [J].Allergol Int,2010,59(4):325-332.
[19] Kambayashi T,Laufer TM.Atypical MHC classⅡ-expressing antigen-presenting cells:can anything replace a dendritic cell?[J].Nat Rev Immunol,2014,14(11):719-730.
Antigen-presenting function of keratinocytes
Hao Junfeng,Jin Liang,Wang Gang.Department of Dermatology,Xijing Hospital,Fourth Military Medical University,Xi′an 710032,China
Keratinocytes not only form physical barriers,but also have important immunologic functions.They can express antigen presentation-related molecules (such as major histocompatibility complex classⅡ (MHC-Ⅱ) and intercellular adhesion molecule-1) with changes of MHC-Ⅰlevels,in some disorders or after stimulation by cytokines such as interferon-γ.In addition,some studies have indicated that activated keratinocytes can process and present endogenous or exogenous antigens to activate antigen-specific T-lymphocytes.This function of keratinocytes is of great significance in elucidating the pathogenesis of related skin diseases and developing specific targeted therapy.Compared with classical antigen-presenting cells,the antigen-presenting function of keratinocytes is somewhat limited.
Keratinocytes;Antigen presentation;T-lymphocytes;Major histocompatibility complex;Cell adhesion molecules
Wang Gang,Email:xjwgang@fmmu.edu.cn
10.3760/cma.j.issn.1673-4173.2015.04.013
王剛,Email:xjwgang@fmmu.edu.cn
2014-12-02)